FortuneIndia

Quick Links :

Fortune 500 India
40 Under 40
Most Powerful Women
Budget 2024
India's Richest
The Next 500
Best B-Schools
Opinion
First Edit
Multimedia
Events

Fortune 500 India
40 Under 40
Most Powerful Women
The Next 500
Best B-Schools
All Rankings
Events
Macro
Enterprise
Technology
Reviews
Venture
Investing
Multimedia
Fortune India Exchange
Bystander
Opinion
Infographics
Ideas
Long Reads
People
Buy on Amazon
Polemicist
Annual Subscription

budesonide inhalation suspension

Share

November 2023

Aurobindo Pharma shares rise 2% on USFDA approval for asthma drug

Aurobindo Pharma shares rise 2% on USFDA approval for asthma drug

Aurobindo Pharma has received approval from USFDA to produce and trade Budesonide Inhalation Suspension

By Fortune India

Advertisement

Top Stories

Fresh US duties on Chinese solar import to trigger India's ascent as global supplier

Fresh US duties on Chinese solar import to trigger India's ascent as global supplier

99% mobiles sold in India are 'Made in India': FM on govt's PLI push

99% mobiles sold in India are 'Made in India': FM on govt's PLI push

M&M shares hit 52-week high on strong Q4; here's what analysts say

M&M shares hit 52-week high on strong Q4; here's what analysts say

UN upgrades India’s 2024 GDP growth forecast to 6.9%

UN upgrades India’s 2024 GDP growth forecast to 6.9%

Vedanta shares up on ₹8,500 cr fundraising plan

Vedanta shares up on ₹8,500 cr fundraising plan

Advertisement

Advertisement

Top Stories

Fresh US duties on Chinese solar import to trigger India's ascent as global supplier

Fresh US duties on Chinese solar import to trigger India's ascent as global supplier

99% mobiles sold in India are 'Made in India': FM on govt's PLI push

99% mobiles sold in India are 'Made in India': FM on govt's PLI push

M&M shares hit 52-week high on strong Q4; here's what analysts say

M&M shares hit 52-week high on strong Q4; here's what analysts say

UN upgrades India’s 2024 GDP growth forecast to 6.9%

UN upgrades India’s 2024 GDP growth forecast to 6.9%

Vedanta shares up on ₹8,500 cr fundraising plan

Vedanta shares up on ₹8,500 cr fundraising plan

Advertisement

Contact Us
Vision & Core Values
Terms of Use
Privacy & Cookie Policy

Powered by Quintype